References
- American Heart Association. International Cardiovascular Disease Statistics — 2004 Update. American Heart Association, TX, USA (2004).
- American Heart Association. Heart Disease and Stroke Statistics — 2004 Update. American Heart Association, TX, USA (2003).
- Smith SC, Blair SN, Bonow RO et al AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update. Circulation 104,1577–1579 (2001).
- Ryan TJ, Antman EM, Brooks NH et al 1999 update: ACC/AHA guidelines for the management of patients with acute myocardial infarction: executive summary and recommendations. Circulation 100, 1016-1030 (1999).
- Jabbour S, Young-Xu Y, Graboys TB et al. Long-term outcomes of optimized medical management of outpatients with stable coronary artery disease. Am. I CardioL 93, 294–299 (2004).
- Allen LA, O'Donnell J, Giugliano RP, Camargo CA, Lloyd-Jones DM. Care concordant with guidelines predicts decreased long-term mortality in patients with unstable angina pectoris and non-ST-elevation myocardial infarction. Am. CardioL 93,1218–1222 (2004).
- Udelson JE, Patten RD, Konstam MA. New concepts in postinfarction ventricular remodeling. Rev Cardiovasc. Med. 4(3), S3—S12 (2003).
- Jacoby DS, Rader DJ. Renin—angiotensin system and atherothrombotic disease. Arch. Intern. Med. 163,1155–1164 (2003).
- Dzau VJ. Tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis. Hypertension 37,1047–1052 (2001).
- Pfeffer MA, Braunwald E, Moye LA et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival and Ventricular Enlargement Trial. N Engl. I Med.327, 669–677 (1992).
- The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet342, 821–828 (1993).
- Swedberg K, Held P, Kjekshus J et al Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction: results of the CO-operative New SCandinavian ENalapril SUrvival Study II (CONSENSUS II). N Engl. J Med. 327, 678–684 (1992).
- Gruppo Italian° per lo Studio della Soprawivenza neffInfarto Miocardico. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet343, 1115–1122 (1994).
- ISIS-4 Collaborative Group. ISIS-4: a randomized factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulfate in 58,050 patients with suspected acute myocardial infarction. Lancet 345, 669–685 (1995).
- Chinese Cardiac Study Collaborative Group. Oral captopril versus placebo among 13,634 patients with suspected acute myocardial infarction: interim report from the Chinese Cardiac Study (CCS-1). Lancet345, 686–687 (1995).
- McMurray JJV. Angiotensin-receptor blockers for chronic heart failure and acute myocardial infarction. Heart 86, 97–103 (2001).
- Rodgers JE, Patterson JH. Angiotensin II- receptor blockers: clinical relevance and therapeutic role. Am. J. Health Syst. Pharm. 58, 671–683 (2001).
- Patterson JH. Angiotensin II receptor blockers in heart failure. Pharmacotherapy 23, 173–182 (2003).
- Dickstein K, Kjekshus J, and the OPTIMAAL Steering Committee for the OPTIMAAL Study Group. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomized trial. Lancet 360, 752–760 (2002).
- •Failed to show that losartan provides an equal or larger reduction in mortality compared with captopril therapy in post-myocardial infarction patients.
- Pitt B, Segal R, Martinex FA et al Randomized trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan In The Elderly study, ELITE). Lancet 349, 747–752 (1997).
- Pitt B, Poole-Wilson PA, Segal R et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomized trial — the Losartan Heart Failure Survival Study Elite II. Lancet355, 1582–1587 (2000).
- Pfeffer MA, McMurray J, Liezorovicz A et al VALsartan In Acute myocardial iNfarction Trial (VALIANT): rationale and design. Am. Heart J. 140, 727–734 (2000).
- Pfeffer MA, McMurray J, Velazquez EJ et al Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl. J Med. 349, 1893–1906 (2003).
- •Demonstrates that the beneficial effects on mortality incidence in post-myocardial infarction patients are similar with valsartan or captopril monotherapy but there is no additional benefit achieved with combination therapy.
- Pitt B, Zannad F, Remme WJ et al The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl. J Med. 341, 709–717 (1999).
- Zannad F, Alla F, Dousset B, Perez A, Pitt B, on behalf of the RALES investigators. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the Randomized ALdactone Evaluation Study (RALES). Circulation 102, 2700–2706 (2000).
- Hayashi M, Tsumatamoto T, Wada A et al Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents postinfarct left ventricular modeling associated with suppression of a marker of collagen synthesis in patients with first anterior acute myocardial infarction. Circulation 107, 2559–2565 (2003).
- Pitt B, Remme W, Zannad F et al. Eplerenone, a selective aldosterone blacker, in patients with left ventricular dysfunction after myocardial infarction. N Engl. J. Med. 348, 1309–1321 (2003).
- •Demonstrates a decrease in mortality and hospitalization due to cardiovascular events when eplerenone therapy is added to standard post-myocardial infarction treatment.
- The Heart Outcomes Prevention Evaluation study investigators. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl. J Med. 342, 145–153 (2000).
- The European Trial On Reduction of Cardiac Events with Perindopril in Stable Coronary Artery Disease investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomized, double-blind, placebo-controlled, multicenter trial (the EUROPA study). Lancet 362, 782–788 (2003).
- •Confirms the results of the Heart Outcomes Prevention Evaluation (HOPE) trial by demonstrating that perindopril therapy decreases the incidence of cardiovascular death, nonfatal myocardial infarction and resuscitated cardiac arrest in patients with coronary heart disease but no heart failure.
- Dzau VJ, Bernstein K, Celermajer D et al. Pathophysiologic and therapeutic importance of tissue ACE: a concensus report. Cardiovasc. Drugs The!: 16, 149–160 (2002).
- Pfeffer MA, Domanski M, Verter J et al. The continuation of the Prevention of Events with Angiotensin-Converting Enzyme inhibition (PEACE) trial. Am. Heart J. 142, 375–377 (2001).
- Unger T The ongoing telmisartan alone and in combination with ramipril global end point trial program. Am. J CardioL 91, G28—G34 (2003).
- Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344, 1383–1389 (1994).
- Shepherd J, Cobbe SM, Ford I et al., for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl. J Med. 333, 1301–1307 (1995).
- The Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl. J Med. 339, 1349–1357 (1998).
- Downs JR, Clearfield M, Weis S et al. Primary prevention of acute coronary events with lovastatin men and women with average cholesterol levels. Results of AFCAPS/TexCAPS. J Am. Med. Assoc. 79, 1615–1622 (1998).
- Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet 360, 7–22 (2002).
- •One of the first landmark trials to demonstrate that reductions in mortality and major vascular events in high-risk patients treated with simvastatin are extended to patients greater than 75 years of age and those with pretreatment low-density lipoprotein (LDL)-cholesterol levels at goal.
- Nissen SE, Tuzcu EM, Schoenhagen P et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis. J. Arn. Med. Assoc. 291(9), 1071–1080 (2004).
- •Proves that more intensive lipid-lowering treatment with high-dose atorvastatin, resulting in mean LDL-cholesterol over 80mg/d1, significantly reduces the progression rate of coronary atherosclerosis compared with a less intensive treatment regimen with pravastatin.
- Cannon CP, Braunwald E, McCabe CH et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N EngL J Med. 350(15), 1495–1504 (2004).
- •Confirms that intensive lipid-lowering treatment with high-dose atorvastatin significantly reduces the incidence of a combined clinical end point of death or major cardiovascular events compared ith a less intensive treatment regimen with pravastatin.
- Maycock CAA, Muhlestein JB, Home BD et al Statin therapy is associated with reduced mortality across all age groups of individuals with significant coronary disease, including very elderly patients. J. Am. Coll. CardioL 40, 1777–1785 (2002).
- •Compares mortality rates of patients with coronary heart disease, stratified by age and treated with or without an HMG-CoA reductase inhibitor. Risk reductions were achieved in all age groups but the greatest risk reductions were seen in patients over 80 years of age.
- Shepherd J, Blauw GJ, Murphy MB et al, on behalf of the PROSPER Study Group. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled trial. Lancet 360,1623–1630 (2002).
- •Confirms the benefits of lipid-lowering therapy in elderly patients by assessing outcomes with pravastatin in patients over 70 years of age.
- Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). J. Arn. Med. Assoc. 285,2486–2497 (2001).
- Isaacsohn JL, Davidson MH, Hunninghake D et al. Aggressive Lipid-Lowering Initiation Abates New Cardiac Events (ALLIANCE) — rationale and design of atorvastatin versus usual care in hypercholesterolemia patients with coronary artery disease. Am. J. CardioL 86(2), 250–252 (2000).
- LaRosa JC. New and emerging data from clinical trials of statins. CUIT: Atheroscler. Rep. 6,12–19 (2004).
- Johnson CL, Rifkind BM, Sempos CT et al. Declining serum total cholesterol levels among US adults: the National Health and Nutrition Examination Surveys. J. Am. Med. Assoc. 269, 3002–3008 (1993).
- Goldbourt U, Yaari S, Medalic JH. Isolated low HDL-cholesterol as a risk factor for coronary heart disease mortality: a 1-year follow-up of 8000 men. Arterioscler. Thromb. Vasc. Biol. 17,107–113 (1997).
- Weverling-Rihnsburger AE, Jonkers IA, Van Exel E et al. High-density vs. low-density lipoprotein cholesterol as the risk factor for coronary artery disease and stroke in old age. Arch. Intern. Med. 163, 1549–1554 (2003).
- Shah P, Amin J. Low high-density lipoprotein level is associated with increased restenosis rate after coronary angioplasty. Circulation 85,1279–1285 (1992).
- Nofer J, Kehrel B, Fobker M et al HDL and arteriosclerosis: beyond reverse cholesterol transport. Atherosclerosis 161, 1–16 (2002).
- Sacks FM, and the Expert Group on HDL-Cholesterol. The role of high-density lipoprotein (HDL) cholesterol in the prevention and treatment of coronary heart disease: expert group recommendations. Am. J. CardioL 90,139–143 (2002).
- McKenney J. New perspectives on the use of niacin in the treatment of lipid disorders. Arch. Intern. Med. 164,697–705 (2004).
- Brown BG, Zhao XQ, Chait A et al Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N EngL Med. 345,1583–1592 (2001).
- •Demonstrates that combination therapy with simvastatin and niacin, by simultaneously targeting LDL and high-density lipoprotein cholesterol, results in a slower progression of coronary lesion stenosis and decreases the incidence of cardiovascular death, nonfatal myocardial infarction or revascularization when compared with placebo.
- Elam MB, Hunninghake DB, Davis KB et al. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: a randomized trial. J Am. Med. Assoc. 284, 1263–1270 (2000).
- Grundy SM, Vega GL, McGovern ME et al. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with Type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial. Arch. Intern. Med. 162,1568–1576 (2002).
- Zhao XQ, Morse JS, Dowdy AA et al Safety and tolerability of simvastatin plus niacin in patients with coronary artery disease and low high-density lipoprotein cholesterol (the HDL Atherosclerosis Treatment Study). Am. J. CardioL 93, 307–312 (2004).
Websites
- National Institute for Clinical Excellence. INHERITED Clinical Guideline A: prophylaxis for patients who have experienced a myocardial infarction www.nice.org.uk (Accessed October 2004)
- Scottish Intercollegiate Guidelines Network. Secondary prevention of coronary heart disease following myocardial infarction www.sign.ac.uk (Accessed October 2004)
- Mosby's Drug Consult www.mosbysdrugconsult.com (Accessed October 2004)
- Boehringer Ingelheim, Inc. ONTARGET News Center www.ontarget-micardis.com/asp/news/ndetail.asp? ID = 1654 (Accessed October 2004)